SG10202011773UA - Neuroactive compounds and methods of use thereof - Google Patents
Neuroactive compounds and methods of use thereofInfo
- Publication number
- SG10202011773UA SG10202011773UA SG10202011773UA SG10202011773UA SG10202011773UA SG 10202011773U A SG10202011773U A SG 10202011773UA SG 10202011773U A SG10202011773U A SG 10202011773UA SG 10202011773U A SG10202011773U A SG 10202011773UA SG 10202011773U A SG10202011773U A SG 10202011773UA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- neuroactive compounds
- neuroactive
- compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462060932P | 2014-10-07 | 2014-10-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10202011773UA true SG10202011773UA (en) | 2021-01-28 |
Family
ID=55653736
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202011773UA SG10202011773UA (en) | 2014-10-07 | 2015-10-07 | Neuroactive compounds and methods of use thereof |
| SG11201702799UA SG11201702799UA (en) | 2014-10-07 | 2015-10-07 | Neuroactive compounds and methods of use thereof |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201702799UA SG11201702799UA (en) | 2014-10-07 | 2015-10-07 | Neuroactive compounds and methods of use thereof |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20170304321A1 (fr) |
| EP (1) | EP3204011A4 (fr) |
| JP (3) | JP2017530982A (fr) |
| KR (1) | KR20170065637A (fr) |
| CN (2) | CN112121171A (fr) |
| AU (2) | AU2015330906A1 (fr) |
| BR (1) | BR112017007053A2 (fr) |
| CA (1) | CA2963938C (fr) |
| IL (2) | IL292465A (fr) |
| MX (2) | MX2017004684A (fr) |
| MY (1) | MY202135A (fr) |
| PE (1) | PE20170907A1 (fr) |
| PH (1) | PH12017500639A1 (fr) |
| RU (1) | RU2764702C2 (fr) |
| SG (2) | SG10202011773UA (fr) |
| WO (1) | WO2016057713A1 (fr) |
| ZA (1) | ZA201702545B (fr) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2951664T3 (es) | 2011-09-08 | 2023-10-24 | Sage Therapeutics Inc | Esteroides neuroactivos, composiciones y usos de los mismos |
| EP3932932A1 (fr) | 2013-03-13 | 2022-01-05 | Sage Therapeutics, Inc. | Stéroïdes neuroactifs et leurs procédés d'utilisation |
| US20160083343A1 (en) | 2013-03-15 | 2016-03-24 | Global Blood Therapeutics, Inc | Compounds and uses thereof for the modulation of hemoglobin |
| EA201992707A1 (ru) | 2013-11-18 | 2020-06-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
| SI3086793T1 (sl) | 2013-12-24 | 2022-10-28 | Virginia Commonwealth University | Uporaba oksigeniranih holesterol sulfatov (OCS) za zdravljenje ledvične disfunkcije |
| EP4306114A1 (fr) | 2014-06-18 | 2024-01-17 | Sage Therapeutics, Inc. | Oxystérols et leurs procédés d'utilisation |
| MY197698A (en) | 2015-07-06 | 2023-07-06 | Sage Therapeutics Inc | Oxysterols and methods of use thereof |
| MA42409A (fr) | 2015-07-06 | 2018-05-16 | Sage Therapeutics Inc | Oxystérols et leurs procédés d'utilisation |
| RU2021100620A (ru) | 2015-07-06 | 2021-01-29 | Сейдж Терапьютикс, Инк. | Оксистеролы и способы их применения |
| LT3436022T (lt) | 2016-04-01 | 2022-06-27 | Sage Therapeutics, Inc. | Oksisteroliai ir jų panaudojimo būdai |
| WO2017193046A1 (fr) | 2016-05-06 | 2017-11-09 | Sage Therapeutics, Inc. | Oxystérols et méthodes d'utilisation associées |
| ES2884071T3 (es) | 2016-07-07 | 2021-12-10 | Sage Therapeutics Inc | 24-hidroxiesteroles sustituidos en 11 para el tratamiento de afecciones relacionadas con NMDA |
| JP2019524772A (ja) * | 2016-08-02 | 2019-09-05 | ヴァージニア コモンウェルス ユニバーシティ | ５−コレステン−３，２５−ジオール，３−サルフェート（２５ｈｃ３ｓ）又は薬学的に許容される塩及び少なくとも１種の環状オリゴ糖を含む組成物 |
| CN110023323A (zh) | 2016-09-30 | 2019-07-16 | 萨奇治疗股份有限公司 | C7取代的氧固醇及其作为nmda调节剂的方法 |
| CA3041088C (fr) * | 2016-10-18 | 2024-05-21 | Sage Therapeutics, Inc. | Oxysterols et leurs procedes d'utilisation |
| MA46565A (fr) | 2016-10-18 | 2019-08-28 | Sage Therapeutics Inc | Oxystérols et leurs procédés d'utilisation |
| EP3335730A1 (fr) * | 2016-12-15 | 2018-06-20 | Fundació Institut de Recerca Biomédica de Bellvitge (IDIBELL) | Composés pour le traitement d'une adrénoleucodystrophie à liaison x |
| US10857163B1 (en) | 2019-09-30 | 2020-12-08 | Athenen Therapeutics, Inc. | Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| WO2006037016A2 (fr) * | 2004-09-27 | 2006-04-06 | The Regents Of The University Of California | Nouvelle therapie destinee au traitement de maladies cerebrales degeneratives chroniques et d'une lesion du systeme nerveux |
| JP2011502974A (ja) * | 2007-11-06 | 2011-01-27 | ナームローゼ・フエンノートチヤツプ・オルガノン | ヒトにおけるホルモン抑制の方法 |
| SG195568A1 (en) * | 2008-05-09 | 2013-12-30 | Univ Emory | Nmda receptor antagonists for the treatment of neuropsychiatric disorders |
| WO2010065709A2 (fr) * | 2008-12-03 | 2010-06-10 | Amin Khan | Dérivés d'acide hydroxamique, préparation et utilisations thérapeutiques de ceux-ci |
| US20110319416A1 (en) * | 2009-01-28 | 2011-12-29 | Emory University | Subunit Selective NMDA Receptor Antagonists For The Treatment Of Neurological Conditions |
| WO2011028794A2 (fr) * | 2009-09-01 | 2011-03-10 | Lazarus Therapeutics, Inc. | Traitement de la chorée de huntington avec de la cyclosérine et un agoniste des récepteurs nmda |
| KR101692275B1 (ko) * | 2010-02-11 | 2017-01-04 | 노오쓰웨스턴 유니버시티 | ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도 |
| US20120035156A1 (en) * | 2010-08-09 | 2012-02-09 | Daniela Alberati | Combination of glyt1 compound with antipsychotics |
| ES2951664T3 (es) * | 2011-09-08 | 2023-10-24 | Sage Therapeutics Inc | Esteroides neuroactivos, composiciones y usos de los mismos |
| WO2013163455A2 (fr) * | 2012-04-25 | 2013-10-31 | The Regents Of The University Of California | Plate-forme de criblage de médicaments pour le syndrome de rett |
| WO2014025942A1 (fr) * | 2012-08-09 | 2014-02-13 | Emory University | Modulateurs de récepteur nmda et utilisations associées à ceux-ci |
| CN105229010A (zh) * | 2013-01-29 | 2016-01-06 | 阿普廷伊克斯股份有限公司 | 螺-内酰胺nmda受体调节剂及其用途 |
| JP2016514967A (ja) * | 2013-03-13 | 2016-05-26 | セージ セラピューティクス， インコーポレイテッド | 神経刺激性ステロイド、組成物およびそれらの使用 |
| EP3932932A1 (fr) | 2013-03-13 | 2022-01-05 | Sage Therapeutics, Inc. | Stéroïdes neuroactifs et leurs procédés d'utilisation |
| EP4306114A1 (fr) * | 2014-06-18 | 2024-01-17 | Sage Therapeutics, Inc. | Oxystérols et leurs procédés d'utilisation |
| WO2016007762A1 (fr) * | 2014-07-09 | 2016-01-14 | Duke University | Compositions et méthodes pour la réparation de la myéline |
| MA42409A (fr) * | 2015-07-06 | 2018-05-16 | Sage Therapeutics Inc | Oxystérols et leurs procédés d'utilisation |
-
2015
- 2015-10-07 AU AU2015330906A patent/AU2015330906A1/en not_active Abandoned
- 2015-10-07 CN CN202011059273.5A patent/CN112121171A/zh active Pending
- 2015-10-07 MY MYPI2017000507A patent/MY202135A/en unknown
- 2015-10-07 PE PE2017000579A patent/PE20170907A1/es unknown
- 2015-10-07 KR KR1020177012221A patent/KR20170065637A/ko not_active Application Discontinuation
- 2015-10-07 CA CA2963938A patent/CA2963938C/fr active Active
- 2015-10-07 MX MX2017004684A patent/MX2017004684A/es unknown
- 2015-10-07 BR BR112017007053A patent/BR112017007053A2/pt not_active Application Discontinuation
- 2015-10-07 SG SG10202011773UA patent/SG10202011773UA/en unknown
- 2015-10-07 JP JP2017518329A patent/JP2017530982A/ja not_active Withdrawn
- 2015-10-07 IL IL292465A patent/IL292465A/en unknown
- 2015-10-07 CN CN201580063540.7A patent/CN107405352A/zh active Pending
- 2015-10-07 EP EP15849514.3A patent/EP3204011A4/fr active Pending
- 2015-10-07 US US15/517,886 patent/US20170304321A1/en not_active Abandoned
- 2015-10-07 WO PCT/US2015/054551 patent/WO2016057713A1/fr active Application Filing
- 2015-10-07 RU RU2017115849A patent/RU2764702C2/ru active
- 2015-10-07 SG SG11201702799UA patent/SG11201702799UA/en unknown
-
2017
- 2017-04-02 IL IL251505A patent/IL251505B/en unknown
- 2017-04-06 PH PH12017500639A patent/PH12017500639A1/en unknown
- 2017-04-07 MX MX2021011939A patent/MX2021011939A/es unknown
- 2017-04-10 ZA ZA2017/02545A patent/ZA201702545B/en unknown
-
2020
- 2020-09-07 JP JP2020149725A patent/JP2020196759A/ja not_active Withdrawn
-
2021
- 2021-02-04 AU AU2021200721A patent/AU2021200721B2/en active Active
-
2022
- 2022-01-05 JP JP2022000454A patent/JP2022033285A/ja active Pending
- 2022-09-19 US US17/947,844 patent/US20230218638A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112017007053A2 (pt) | 2018-06-19 |
| AU2021200721B2 (en) | 2023-06-01 |
| JP2017530982A (ja) | 2017-10-19 |
| MX2017004684A (es) | 2017-06-30 |
| ZA201702545B (en) | 2019-06-26 |
| PE20170907A1 (es) | 2017-07-12 |
| JP2020196759A (ja) | 2020-12-10 |
| IL251505A0 (en) | 2017-05-29 |
| US20230218638A1 (en) | 2023-07-13 |
| PH12017500639A1 (en) | 2017-09-25 |
| SG11201702799UA (en) | 2017-05-30 |
| RU2764702C2 (ru) | 2022-01-19 |
| CA2963938C (fr) | 2023-10-24 |
| MY202135A (en) | 2024-04-05 |
| EP3204011A4 (fr) | 2018-06-20 |
| CA2963938A1 (fr) | 2016-04-14 |
| AU2021200721A1 (en) | 2021-03-04 |
| CN107405352A (zh) | 2017-11-28 |
| KR20170065637A (ko) | 2017-06-13 |
| CN112121171A (zh) | 2020-12-25 |
| MX2021011939A (es) | 2021-11-03 |
| WO2016057713A1 (fr) | 2016-04-14 |
| EP3204011A1 (fr) | 2017-08-16 |
| IL292465A (en) | 2022-06-01 |
| AU2015330906A1 (en) | 2017-04-27 |
| RU2017115849A (ru) | 2018-11-13 |
| NZ730862A (en) | 2024-01-26 |
| JP2022033285A (ja) | 2022-02-28 |
| IL251505B (en) | 2022-05-01 |
| US20170304321A1 (en) | 2017-10-26 |
| RU2017115849A3 (fr) | 2019-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL276946A (en) | Antiproliferative compounds and methods of use | |
| ZA201702545B (en) | Neuroactive compounds and methods of use thereof | |
| IL250415B (en) | Antibodies against pd-l and methods of using them | |
| IL278574B1 (en) | Compounds acting on glycans and methods of using them | |
| HK1253049A1 (zh) | 糖基相互作用化合物及其使用方法 | |
| HRP20190432T1 (hr) | Spojevi pladienolid piridina i postupci uporabe | |
| HUE056172T2 (hu) | Szelenoorganikus vegyületeket tartalmazó készítmények és eljárások alkalmazásukra | |
| RS60718B1 (sr) | Jedinjenja i načini upotrebe | |
| ZA201606450B (en) | Compounds and their methods of use | |
| GB201403697D0 (en) | Compounds and methods of use | |
| GB201416797D0 (en) | Contianer and method of use thereof |